Want to see TSE:OVAT full AI Analyst Report?
OVAT Stock Chart & Stats
C$0.04
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.04
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.02 - C$0.06
Previous CloseN/A
Volume0.00
Average Volume (3M)3.74K
Market Cap
C$576.63K
Enterprise ValueC$726.71K
Total Cash (Recent Filing)C$72.29K
Total Debt (Recent Filing)C$283.06K
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding38,441,680
10 Day Avg. Volume3,400
30 Day Avg. Volume3,744
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)-0.98
Price to Sales (P/S)20.98
P/FCF Ratio-18.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Transdermal PlatformOwning a proprietary skin-delivery platform is a durable competitive asset: it enables differentiated finished products, supports product pipeline expansion across cosmetic and therapeutic uses, and creates intellectual property that can sustain pricing power and barriers to entry over months to years.
Flexible Revenue Model (product + B2B)A dual commercial pathway—direct finished-product sales plus potential B2B licensing—provides structural optionality. It lets the company diversify revenue streams, scale via partners without full commercial investment, and monetize IP, reducing sole reliance on end-customer channels over a multi-month horizon.
Improving Cash-burn TrendAn improving cash-burn trend suggests stronger cost controls or operational efficiencies are taking hold. While cash flow remains negative, the directional improvement reduces near-term external funding pressure and can be a foundation for sustained stabilization if continued over the next several quarters.
Bears Say
Persistent Net Losses & Negative MarginsConsistent, deep losses and a 2025 gross loss indicate the core business is not yet profitable. This undermines internal capital generation, constrains reinvestment in R&D and commercialization, and raises the risk that durable margin recovery will require material business model or cost-structure changes.
Strained Balance Sheet; Negative EquityNegative equity and rising debt signal accumulated losses and limited balance-sheet flexibility. This structural weakness reduces access to low-cost capital, increases refinancing and solvency risk, and constrains the company's ability to fund product development or scale commercial efforts without dilutive or costly financing.
Small, Volatile Revenue And Ongoing Cash BurnLow and volatile revenue makes revenue predictability and economies of scale difficult to achieve. Persistent negative cash flow forces reliance on external funding, which may be limited by the weak balance sheet, increasing the structural risk that operations cannot be sustained without new capital or a material business turnaround.
Ovation Science News
OVAT FAQ
What was Ovation Science Inc’s price range in the past 12 months?
Ovation Science Inc lowest stock price was C$0.01 and its highest was C$0.06 in the past 12 months.
What is Ovation Science Inc’s market cap?
Ovation Science Inc’s market cap is C$576.63K.
When is Ovation Science Inc’s upcoming earnings report date?
Ovation Science Inc’s upcoming earnings report date is Aug 21, 2026 which is in 49 days.
How were Ovation Science Inc’s earnings last quarter?
Currently, no data Available
Is Ovation Science Inc overvalued?
According to Wall Street analysts Ovation Science Inc’s price is currently Overvalued.
Does Ovation Science Inc pay dividends?
Ovation Science Inc does not currently pay dividends.
What is Ovation Science Inc’s EPS estimate?
Ovation Science Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ovation Science Inc have?
Ovation Science Inc has 38,441,680 shares outstanding.
What happened to Ovation Science Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Ovation Science Inc?
Currently, no hedge funds are holding shares in TSE:OVAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ovation Science Inc
Ovation Science Inc. specializes in the creation of cannabis and hemp-based products, distributed across Canada, the United States, and Mexico. A cornerstone of its offerings is Invisicare, a patented drug delivery technology employed in topical and transdermal skincare formulations. This system integrates hemp seed oil and cannabis, underpinning the company's Ovation and BASKiN brands. Additionally, Ovation Science provides a diverse product portfolio including Invibe MD for CBD-infused health and wellness, ARLO CBD for skincare, and DermSafe for hand sanitizers. The company possesses sublicenses for its cannabis product lines and utilizes its Lighthouse initiative to engage with licensed dispensaries throughout the United States. Founded in 2017, Ovation Science Inc. is based in Vancouver, Canada.
Technical Analysis
Willow Biosciences Inc
―
MediPharm Labs
―
Nextleaf Solutions
―
Vext Science
―
BioNxt Solutions
―